Full Press Release Details
Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML.
ARGX
Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML
Key Takeaway: Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis